Tirzepatide has potential to drive weight loss market dramatically, observes GlobalData
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
The company exports mobile surgery equipment to over 100 countries from Pune
The company also raised Rs 270 crore investment from Temasek in 2019
The company intends to begin using drones to make deliveries of critical and emergency medical supplies, vaccines, and lifesaving drugs after getting the prerequisite regulatory approvals
The campaign will be available in nine Indian languages namely Hindi, English, Odia, Marathi, Tamil, Telugu, Kannada, Malayalam and Bengali
This partnership expands DNA Script’s footprint and provides sales and support for the SYNTAX System DNA printer in labs in India
Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
The round also saw participation from US-based fund 57 Stars, a few prominent angel investors, existing investors Stellaris Venture Partners, Vertex Ventures, and Alteria Capital
Subscribe To Our Newsletter & Stay Updated